Realcan Pharmaceutical Group Management
Management criteria checks 3/4
Realcan Pharmaceutical Group's CEO is Xu Han, appointed in May 2023, has a tenure of 15.5 years. directly owns 12.4% of the company’s shares, worth CN¥563.90M. The average tenure of the management team and the board of directors is 3 years and 3.6 years respectively.
Key information
Xu Han
Chief executive officer
CN¥535.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2yrs |
| CEO ownership | 12.4% |
| Management average tenure | 3yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
We Think Realcan Pharmaceutical Group (SZSE:002589) Has A Fair Chunk Of Debt
Dec 12
Realcan Pharmaceutical Group (SZSE:002589) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 06Improved Revenues Required Before Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) Stock's 36% Jump Looks Justified
Oct 18Realcan Pharmaceutical Group's (SZSE:002589) Earnings Seem To Be Promising
May 06CEO
Xu Han (59 yo)
2yrs
Tenure
CN¥535,500
Compensation
Mr. Xu Han serves as the Chairman of the Board of Directors at Realcan Pharmaceutical Group Co., Ltd. and has been its Director since November 21, 2009 and has been its President since May 26, 2023.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Chairman | 2yrs | CN¥535.50k | 12.4% CN¥ 563.9m | |
| CFO & VP | 4.1yrs | CN¥275.10k | no data | |
| VP & Director | no data | CN¥240.60k | no data | |
| VP & Director | no data | CN¥907.70k | no data | |
| VP, Secretary & Director | 1.8yrs | CN¥287.40k | no data | |
| Vice President | 15.5yrs | CN¥274.30k | no data |
3.0yrs
Average Tenure
47.5yo
Average Age
Experienced Management: 002589's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Chairman | 15.5yrs | CN¥535.50k | 12.4% CN¥ 563.9m | |
| VP & Director | 15.5yrs | CN¥240.60k | no data | |
| VP & Director | 5.6yrs | CN¥907.70k | no data | |
| VP, Secretary & Director | 2yrs | CN¥287.40k | no data | |
| Director | 2yrs | CN¥192.00k | no data | |
| Supervisor | 15.5yrs | no data | no data | |
| Employee Representative Supervisor | 15.5yrs | no data | no data | |
| Independent Director | 5.2yrs | CN¥60.00k | no data | |
| Director | 2yrs | CN¥242.80k | no data | |
| Independent Director | 2yrs | CN¥36.90k | no data | |
| Independent Director | 2yrs | CN¥36.90k | no data | |
| Chairman of the Supervisory Board | 2yrs | no data | no data |
3.6yrs
Average Tenure
47.5yo
Average Age
Experienced Board: 002589's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 20:27 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Realcan Pharmaceutical Group Co., Ltd. is covered by 17 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Xu Qing Liu | Chasing Securities |